Robert Koch was right. Towards a new interpretation of tuberculin therapy;Robert Koch tenía razón. Hacia una nueva interpretació n de la terapia con tuberculina

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 6, 2006, Pages 385-391

  Cardona, Pere J ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Historia; Inmunoterapia; Mycobacterium vaccae; Robert Koch; RUTI; Tuberculina

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; GERMANY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOTHERAPY; INOCULATION; MORTALITY; MYCOBACTERIUM VACCAE; SHORT COURSE THERAPY; TH1 CELL; TREATMENT FAILURE; TUBERCULIN TEST; TUBERCULOSIS;

EID: 33746478104     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13089694     Document Type: Article

References (30)

1. Kaufmann SH, Schaible UE. 100th anniversary of Robert Koch's Nobel Prize for the discovery of the tubercle bacillus. Trends Microbiol 2005;13:469-75.
2. Kaufmann SH. Robert Koch, the Nobel Prize, and the ongoing threat of tuberculosis. N Engl J Med. 2005;353:2423-6.
3. Kaufmann SH. Introduction. Rational vaccine development against tuberculosis: Those who don't remember the past are condemned to repeat it. Microbes Infect. 2005;7:897-8.
4. Gradmann C. Robert Koch and the white death: from tuberculosis to tuberculin. Microb Infect 2005; In Press, Corrected Proof, Available online 8 August 2005.
5. Dubos R, Dubos J. The white plague. Tuberculosis, man, and society. New Brunswick: 3rd ed. Rutgers University Press; 1996.
6. Brock TD. Robert Koch, a life in medicine and bacteriology. Washington: ASM Press; 1999.
7. Burke DS. Of postulates and peccadilloes: Robert Koch and vaccine (tuberculin) therapy for tuberculosis. Vaccine. 1993;11:795-804.
8. Gradmann C. Money and microbes: Robert Koch, tuberculin and the foundation of the institute for infectious diseases in Berlin in 1891. Hist Philos Life Sci. 2000;22:59-79.
9. Unger U. Robert Koch. Roman eines grossen lebens. Berlin: Neues Volk; 1936.
10. Burke DS. Vaccine therapy for HIV: a historical review of the treatment of infectious diseases by active specific immunisation with microbe-derived antigens. Vaccine. 1993;11:883-91.
11. Daniel TM. Captain of death: the story of tuberculosis. University of Rochester Press; 1999.
12. Keers. Pulmonary tuberculosis. A journey down the centuries. London: Baillière Tindall; 1978.
13. Dormandy T. The white death. A history of tuberculosis. New York: New York University Press; 2000.
14. Benedeck TG. The history of gold therapy for tuberculosis. J Hist Med All Sc. 2004;59:50-89.
15. Doenhoff MJ. Granulomatous inflammation and the transmisión of infection: schistosomiasis-and TB too). Immunol Today. 1998;19:462-6.
16. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Bios. 2004;9:1701-19.
17. Bonime E. Tuberculin and vaccine in tubercular affections: a practical guide for the utilization of the immune response in general practice. New York: Southwort, Troy; 1917.
18. Cochrane AWR, Sprawson CA. A guide to the use of tuberculin. New Cork: William Word; 1917.
19. Darier A. Vacuna sueros y fermentos en la práctica diaria. En: Mariano Roig SC, editor. Barcelona; 1918.
20. Pereira Poza A. La paciencia al sol. Historia social de la tuberculosis en Galicia (1900-1950). Sada-A Coruña: Edicios do Castro; 1999.
21. Riviére, C. Tuberculin treatment. Lancet. 1912;I:147.
22. Pottenger FM. Tuberculosis. A discussion of phthisiogenesis, immunology, pathologic physiology, diagnosis, and treatment. St. Louis: C.V. Mosby; 1948. p. 437-56.
23. Davies RPO, Tocque K, Bellis MA, Rimmington T, Davies PDO. Historical declines in tuberculosis in Endland and Wales: improving social conditions or natural selection? Int J Tuber Lung Dis. 1999;3:1051-4.
24. Lipsitch M, Sousa AO. Historical intensity of natural selection for resistance to tuberculosis. Genetics. 2002;161:1599-607.
25. Mitchison DA, Dickinson JM. Bactericidal mechanisms in short-course chemotherapy. Bull Int Union Against Tuberc. 1978;53:254-9.
26. Cardona PJ, Amat I. Origen y desarrollo de RUTI, una nueva vacuna terapéutica contra la infección por Mycobacterium tuberculosis. Arch Bronconeumol. 2006;42:25-32.
27. Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Díaz J, et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine. 2005;23:1393-8.
28. Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis. 2006;86:273-89.
29. Cardona PJ, Llatjós R, Gordillo S, Viñado B, Díaz J, Ariza A, et al. Towards a "human-like" model of tuberculosis: Local inoculation of LPS in lungs of Mycobacterium tuberculosis aerogenically infected mice induces intragranulomatous necrosis. Scand J Immunol. 2001;53:65-71.
30. Guirado E, Amat I, Gil O, Díaz J, Arcos V, Cáceres N, et al. Passive serum-therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against pot-chemotherapy relapse of tuberculosis infection in SCID mice. Microb Infect. 2006. [On line desde el 27 de enero de 2005.]